You are here

Company Discovers New Antibiotic Compound

The compound, AQP-182, has demonstrated bactericidal potency against multidrug-resistant Staphylococcus aureus (MDRSA), multidrug-resistant Streptococcus pneumoniae (MDRSP), Clostridium difficile, and Enteroccocus faecalis—common causes of death in patients in hospital care units.

AQP-182 is one of the novel drug-like molecules identified by Aquapharm from its collection of more than 10,000 marine microorganisms. The company has identified 16 molecules of interest. AQP-182 is the most advanced of these molecules because of its activity against multi–drug-resistant gram-positive bacteria, with in vitro minimum inhibitory concentrations against MDRSA below 0.016 mcg/mL.

Aquapharm expects to initiate a phase I clinical study of AQP-182 in the second half of 2013.

For more information, visit the Aquapharm Biodiscovery Web site.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress